Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.

Ronald de Vries graduated in Organic and Analytical Chemistry at the Free University of Amsterdam, The Netherlands. After working in a Contract Laboratory (CRO) for 7 years, he joined Janssen R&D in 1998. At Janssen R&D, Belgium, Ronald worked in the bioanalytical department that supports both clinical and nonclinical bioanalysis. In this department he had several roles, such as providing the bioanalytical support for various drug development programs and leading the method establishment group. He has done numerous global assay transfers to/from Janssen from/to other laboratories and plays an important role in the introduction and application of new technologies and applied innovation in the department. In 2014 he started in the drug metabolism and pharmacokinetics department of Janssen R&D, where his main tasks are in vivo and in vitro metabolite identification using high resolution MS and Radiodetection.

[1]  A. Rosenwald,et al.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. , 2014, The Lancet. Oncology.

[2]  J. Pinilla-Ibarz,et al.  Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. , 2014, P & T : a peer-reviewed journal for formulary management.

[3]  Naidong Weng,et al.  Mini FocuS iSSue : tieRed appRoach to BioanalySiS , 2014 .

[4]  Magnus Knutsson,et al.  Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum. , 2009, Bioanalysis.

[5]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[6]  M. Rangasamy,et al.  Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. , 2015, Journal of pharmaceutical and biomedical analysis.

[7]  Y. Alnouti,et al.  The profile of bile acids and their sulfate metabolites in human urine and serum. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  J. Castillo,et al.  PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies , 2012, Expert opinion on investigational drugs.

[9]  Vinod P. Shah,et al.  Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007 .

[10]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[11]  M. T. Donato,et al.  Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method[S] , 2012, Journal of Lipid Research.

[12]  L. Leclercq,et al.  Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men , 2015, Drug Metabolism and Disposition.

[13]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[14]  Vinod P. Shah,et al.  Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays , 2007 .

[15]  Y. Alnouti.  Bile Acid sulfation: a pathway of bile acid elimination and detoxification. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[17]  M. Fouad,et al.  Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection , 2015, Journal of analytical methods in chemistry.

[18]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[19]  R. J. Briggs,et al.  Method Transfer, Partial Validation, and Cross Validation: Recommendations for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team , 2014, The AAPS Journal.

[20]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Jennifer R. Brown.  Ibrutinib in chronic lymphocytic leukemia and B cell malignancies , 2014, Leukemia and Lymphoma.

[22]  G. Neale,et al.  Serum bile acids in liver disease , 1971, Gut.